drugset

Drugs / Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)

Follow last change Jun 2025 re-read 3 minutes ago

Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)

also known as Recombinant RSV vaccine(CHO cells)

Developed for: respiratory syncytial virus infectious disease
Investigated by: Henan Center for Disease Control and Prevention · MAXVAX Biotechnology Limited Liability Company

Trials 1

today NCT06642558 · Ph 1/2

20252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/2	NCT06642558	Nov 2024 → Jun 2025 overdue	respiratory syncytial virus infectious disease	MAXVAX Biotechnology Limited Liability Company	Active not recruiting	No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06642558 ↗
Known as	Recombinant RSV vaccine(CHO cells)	“two dose levels of the single dose Recombinant RSV vaccine(CHO cells), when administered intramuscularly (IM)” NCT06642558 ↗
Modality	Vaccine	“Recombinant RSV vaccine(CHO cells)” NCT06642558 ↗
Route	Intramuscular	“when administered intramuscularly (IM)” NCT06642558 ↗